Scientific Name: (Growth Hormone-Releasing Peptide 2) – GHRP-2
Clinical Test Expectation: Stimulation of GH secretion. Fat mass decrease. Muscle mass increase. Lowering of cholesterol level. Skin and bones state improvement. Defence of the liver and anti-inflammatory action.
MG Strength: 10mg per vial
Detailed Product Information
Amino acid sequence: D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2 Formula: C45H55N9O6 Mol. Mass: 817.9 g/mol Half-life: Between 15 and 60 minutes
Appearance: Sterile Filtered White lyophilized (freeze-dried) powder. Growth hormone releasing peptide (GHRP-2) is the most potent of the GH secretagogues.
Growth hormone secretagogues stimulate the anterior pituitary gland causing an increase in GH release. This was demonstrated in an early study, GHRP-2 (also known as KP-102) was tested on adult male rats: KP-102 induced a large plasma GH response at a dose of 0.5 micrograms/kg BW in conscious rats, although GH-releasing abilities of KP-102 varied markedly depending on the phase of GH secretion. It produced a large plasma GH response in the presence of exogenous GH-releasing factor (GRF). During intermittent administration of GRF, the somatotropes became refractory to a large bolus dose of GRF, but KP-102 induced a marked increase of plasma GH. KP-102 and GRF acted synergistically on GH secretion in control animals. Taken together, these findings suggest that the KP-102-induced GH secretion largely depends on GRF and the secretagogue potentiates the GRF effect by antagonizing the SS action at the level of somatotropes.
It is concluded that KP-102 alone or in combination with GRF provides a means of stimulating GH secretion in the face of elevated inhibitory tone.
 Concerning the safety of the peptide, a study showed no serious general pharmacological effects at pharmacological doses: The general pharmacological effects of the hexapeptide KP-102 (growth hormone-releasing peptide-2), which potently promotes growth hormone (GH) release by acting at both hypothalamic and pituitary sites, were evaluated in various animal experimental models. The administration of KP-102 showed no obvious effect at a pharmacological dose on the central nervous system. KP-102 had no significant effect on the autonomic nervous system and smooth muscle except a slight and transient increase in spontaneous motility of isolated rabbit ileum and contraction of isolated guinea pig ileum at high doses. There was negligible effect on the respiratory and cardiovascular systems, digestive system, renal function and blood system after KP-102 treatment. These results suggest that KP-102 has no serious general pharmacological effects at dose levels showing GH-releasing activity in the experimental animals. Therefore, it is concluded that KP-102 will be a useful drug for the diagnosis of serious GH deficiency and for treatment of short stature.
 Types of administration have been studied closely and compared for availability and use in stature disorders: GH secretion is primarily regulated by the hypothalamic-releasing hormones GHRH and somatostatin. Additionally, several neurotransmitters act at the hypothalamus and pituitary to modulate GH release. The agents commonly used in clinical practice to diagnose GH deficiency, such as arginine, insulin and L-dopa, act through the neural GH network. Many children with a poor GH response to conventional agents have a significant serum GH response to iv GHRH. GH-releasing peptides (GHRPs) are synthetic peptides that like GHRH act directly on pituitary somatotrophs to stimulate GH release. GHRP-2, an investigational drug, is one of the most potent members of the GHRP family. It has been shown to be effective in adults via the oral and intranasal as well as the iv route of administration. In this study, GH responses to GHRP-2 were compared with GH responses to other provocative agents in children of short stature. GHRP-2 peptides were administered iv or intranasally to children with short stature. In the same subjects, GHRP-2 was administered iv in combination with GHRH. Twenty-four children undergoing evaluation for GH deficiency received at least one conventional agent (arginine, L-dopa/exercise, insulin) in addition to iv GHRH and GHRP-2. The GH responses to GHRH or GHRP-2 were similar in each child, and both were equally reliable predictors of pituitary reserve. The conventional agents used in GH testing were less likely to predict the capacity of the pituitary to release GH than were either GHRH or GHRP-2. There was no correlation between maximal GH response to standard tests with GH responses to GHRH or GHRP-2. A subset of the group of 21 children who had a robust response to iv GHRP-2 were later administered GHRH+GHRP-2 simultaneously. The GH response to GHRH+GHRP-2 was synergistic in this group of 12 children, similar to previously reported observations in adults of normal stature. Fifteen of the 21 children who had a robust response to the iv GH-releasing factors also received intranasal GHRP-2. All 15 of these children had a significant GH response to intranasal GHRP-2 over a dose range of 5-20 micrograms/kg per dose. The mean peak GH response to 15 micrograms/kg was 31.3 micrograms/L. The intranasal preparation was well tolerated.
 The Pediatric Department at a University in Spain gathered known info through 1996 and summarized it: Growth hormone (GH)-releasing peptides (GHRPs), a family of synthetic oligopeptides which stimulate GH release, were identified more than a decade ago. The effects of these peptides on GH release have been described in vivo and in vitro, in both animals and humans, using various doses and administration routes. It is generally accepted that GHRPs stimulate the release of GH by acting at the level of the pituitary through a receptor different to that for the endogenous GH-releasing hormone (GHRH). In addition, it has been reported that there are specific binding sites for these peptides in the hypothalamus and that systemic administration of GHRPs increases the expression of the immediate early gene c-fos in a subpopulation of hypothalamic neurons. However, the identity of these hypothalamic neurons and the mechanism of action of GHRPs at both the hypothalamic and pituitary levels remain unknown. One interesting aspect of GHRPs is that they are orally active and this phenomenon has been demonstrated in both animals and humans. Furthermore, these drugs stimulate GH secretion in humans dose-dependently with the magnitude and duration of this response being comparable to that seen with an intravenous peptide bolus. We have studied the oral activity of GHRP-2 on GH release in normal children. In addition, we have analyzed the response to GHRP-2 of obese adolescents, as well as the effects of an intravenous bolus of GHRH alone and GHRH plus GHRP-2. Orally administered GHRP-2 stimulates GH secretion in normal children and, although it seems that this drug is more potent in girls, there were no statistical differences between the groups. Characteristically, GH levels started to increase by 15 min, peaked at 60 min and returned to basal concentrations by 180 min. The effect of GHRP-2 was synergistic with GHRH 1-29 NH2.
 Recent findings have shown GHRP-2 GH release in little GH deficient mice to be from 9 to 160 fold increase over the control group: To investigate a possible direct, growth hormone-releasing, hormone-independent action of a growth hormone secretagogue, GHRP-2, in pituitary somatotroph cells in the presence of inactive growth hormone releasing hormone receptors. The responses of serum growth hormone to acutely injected growth hormone-releasing P-2 in lit/lit mice, which represent a model of GH deficiency arising from mutated growth hormone-releasing hormone receptors, were compared to those observed in the heterozygous (lit/+) littermates and wild-type (+/+) C57BL/6J mice. After the administration of 10 mcg of growth hormone-releasing P-2 to lit/lit mice, a growth hormone release of 9.3±1.5 ng/ml was observed compared with 1.04±1.15 ng/ml in controls (p<0.001). In comparison, an intermediate growth hormone release of 34.5±9.7 ng/ml and a higher growth hormone release of 163±46 ng/ml were induced in the lit/+ mice and wild-type mice, respectively. Thus, GHRP-2 stimulated growth hormone in the lit/lit mice, and the release of growth hormone in vivo may be only partially dependent on growth hormone-releasing hormone. Additionally, the plasma leptin and ghrelin levels were evaluated in the lit/lit mice under basal and stimulated conditions. Here, we have demonstrated that lit/lit mice, which harbor a germline mutation in the Growth hormone-releasing hormone gene, maintain a limited but statistically significant growth hormone elevation after exogenous stimulation with GHRP-2. The present data probably reflect a direct, growth hormone-independent effect on Growth hormone S (ghrelin) stimulation in the remaining pituitary somatotrophs of little mice that is mediated by growth hormone S-R 1a.
 Generally, medical study grade peptides are used for these tests. This correlates to 95% purity or better. Testing with research items with lower purity would not yield the same test results. Here is a link to our latest batch showing purity of the sequence.
Reconstitution : As a general procedure, the manufacturer recommends reconstituting GHRP-2 peptides in sterile, distilled water, with light sonication if necessary.
Any questions about personal GHRP-2 peptide use including, but not limited to bodybuilding, dosing, injections or cycling will be added to our DO NOT SELL LIST.
 Sawada H. Effect of newly developed analogue of growth hormone releasing peptide [D-Ala-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2 (KP-102)] on growth hormone secretion in adult male rats. Third Department of Internal Medicine, Nippon Medical School, Tokyo, Japan. Nihon Ika Daigaku Zasshi. 1995 Apr;62(2):142-9.
 Furuta S, Shimada O, Doi N, Ukai K, Nakagawa T, Watanabe J, Imaizumi M. General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12):868-80.
 Pihoker C, Middleton R, Reynolds GA, Bowers CY, Badger TM. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature. Journal of Clinical Endocrinology and Metabolism. 1995 Oct;80(10):2987-92.
 Argente J, García-Segura LM, Pozo J, Chowen JA. Growth hormone-releasing peptides: clinical and basic aspects. Horm Res. 1996;46(4-5):155-9.
 Peroni CN, Hayashida CY, Nascimento N, Longuini VC, Toledo RA, Bartolini P, Bowers CY, Toledo SP. Growth hormone response to growth hormone-releasing peptide-2 in growth hormone-deficient Little mice. Clinics (Sao Paulo). 2012;67(3):265-72
Mixing and our recommended dosage
You inject 3ml water into the vial of GHRP 2 from the water vial. 1 full syringe is 1ml. You then wait for the vial powder content to dissolve ON ITS OWN. DO NOT SHAKE THE VIAL TO MIX POWDER. Once dissolved and clear in colour you draw out 0.1 (or 3iu) on the syringe each morning before breakfast, 0.1 (or 3iu) before lunch and 0.1 (or 3iu) before bed and inject it into the tummy under the skin into the fatty skin layer. This is a total of 0.3 (or 9iu) a day, A vial should last 10 days.
Read more about our products here : FAQ’s
View more products here : More Products
Affiliate Partner : Visit Now